Etesevimab and Bamlanivimab

In: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006.


The distribution of etesevimab and bamlanivimab was stopped in June of 2021 because of a lack of efficacy against COVID-19 variants. Etesevimab and bamlanivimab are monoclonal antibodies directed against the SARS-CoV-2 virus that causes COVID-19. No information is available on their clinical use during breastfeeding. Because etesevimab and bamlanivimab are large protein molecules with molecular weights of 146,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2]

Publication types

  • Review